Press Release

 SN Nuclearelectrica SA Signs Strategic Agreements with French EDF Group for Cernavoda Unit 1 Refurbishment and Medical Radioisotopes Project

 Bucharest, October 8, 2025

SN Nuclearelectrica SA (SNN), has ceremonially signed  two agreements with French EDF Group subsidiaries. The first agreement, signed  with Arabelle Solutions, aims at advancing the refurbishment of Unit 1 at the Cernavoda Nuclear Power Plant. The second agreement with Framatome is focused on the development of the Medical Radioisotopes Project. These agreements follow SNN’s investment strategy and its objective to place the Romanian nuclear industry at the forefront of global nuclear current and future trends.

 Arabelle Solutions will provide equipment and services for the refurbishment of the Turbine-generator of Cernavoda NPP Unit 1, as part of refurbishment of Unit 1, and consequently its life extension with additional 30 years, starting 2029.

Refurbishment of Cernavoda NPP Unit 1 is in its second phase of development focusing mainly on engineering, procurement, permits, financing, planning and infrastructure construction. Nuclearelectrica already started the civil constructions for the refurbishment of Unit 1. Unit 1, as established during the 3rd and last stage of implementation, will be disconnected from the grid in 2027 and recommissioned in 2029. It will continue to deliver safely, 24/7, 5 million MWh/year and avoid 5 million tonnes of CO2/year, while developing the supply chain and providing hundreads of jobs.

“Our goal is to provide Romania with energy security, clean energy, and standards of excellence through international partnerships, expertise, and local and national development. We have taken essential steps in developing SNN’s strategic projects in 2024 and 2025. Through our strategies and projects, we want to contribute not only to energy security and the achievement of decarbonization and ESG targets, but also to areas where nuclear energy can prove its usefulness. As a critical aspect to support all our projects, we are equally concerned with nurturing a new generation of specialists in Romania”.- Cosmin Ghita, Chief Executive Officer Nuclearelectrica

The agreement with Framatome establishes the framework under which Framatome and SNN will collaborate to implement the production of Lutetium 177 medical radioisotopes at Cernavoda NPP, operate the equipment and infrastructure resulting from the implementation of this project and, in the future, develop other projects related to the production of medical radioisotopes.

Initiated in 2024, as part of Nuclearelectrica’s long-term strategy to capitalize on the additional advantages of nuclear energy production and provide the medical industry with much needed medical radioisotopes, the  IRIS (Innovative Romanian Isotope System) Project has now entered into its effective implementation, Nuclearelectrica and Framatome’s objective being to launch the irradiation commercial service in 2028. 

More than 10,000 medical care units worldwide, totalling approximately 49 million radioisotopes procedures/year and more than 1,500 medical care units in EU, with 10 million procedures/year provide a clear dimension of the radioisotopes need and role, hence the contribution Nuclearelectrica can make is all the more important, Lutetium 177 being an essential cancer treatment isotope.

„2025 is significant in terms of project development and advancement at Nuclearelectrica. We are aligned with our established calendar and every agreement is destined to take both the Refurbishment of Unit 1 and the IRIS Project one step ahead towards completion. We partner with top professionals worldwide, such as Arabelle Solutions and Framatome, to provide energy security, security of supply, clean energy on one hand, with the Refurbishment of Unit 1 and radioisotopes for the medical community, and, at the same time, added value for our shareholders. We are here to prove the full beneficial range of the Romanian nuclear industry.”-Cosmin Ghita, Chief Executive Officer Nuclearelectrica

“We are proud to support the refurbishment of Cernavoda Unit 1, a project of strategic importance for Romania’s energy future. This contract reflects our commitment to delivering proven, reliable, and innovative technologies that enable the safe, long-term operation of nuclear assets, while providing reliable, low-carbon electricity to future generations”, explains Catherine Cornand, CEO of Arabelle Solutions.

“This agreement underscores Framatome and Nuclearelectrica’s commitment to strengthening the supply chain for lifesaving radioisotopes in Europe and across the globe,” said Grégoire Ponchon, CEO of Framatome. “Framatome is proud to leverage its expertise in the fight against cancer and help facilitate mass access to nuclear medicine.”

In a global context where energy security, decarbonization, and technological innovation are strategic imperatives, Nuclearelectrica is accelerating its investments in expanding production capacities and developing unique projects at the European level.